Clinical Trials Browser

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

269 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03428958 2025-04-23

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase 1/2 Recruiting

51 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04456699 2024-10-29

LYNK-003

Phase 3 Completed

335 enrolled 19 charts

Gastrointestinal

Colorectal Neoplasms

NCT03698461 2024-01-31

CLIMB

Phase 2 Completed

20 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT06197438 2024-01-09

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Phase 2 Unknown

36 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05839470 2023-11-15

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Phase 2 Unknown

20 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01681472 2020-09-25

PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

Phase 1/2 Completed

32 enrolled 52 charts

Gastrointestinal

Colonic Neoplasms, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03300609 2020-06-11

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Phase 3 Terminated

4 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01789723 2020-01-23

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Phase 1 Withdrawn

Lymphoid

Lymphoma, Non-Hodgkin

NCT01820091 2020-01-23

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Phase 1 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03222089 2018-03-27

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT01895257 2017-07-07

Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer

Phase 3 Unknown

162 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01611857 2016-11-23

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Phase 1/2 Completed

49 enrolled 12 charts

GastrointestinalOther solid neoplasm

Malignant Solid Tumour

NCT00865709 2014-12-11

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

Phase 2 Completed

198 enrolled 18 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Clinical Trials

MK-3475-06C

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

KEYNOTE 975

OrigAMI-2

OrigAMI-3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

MOUNTAINEER-03

MK-3475-06E

MK-9999-02A

MK-7902-014

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

LYNK-003

CLIMB

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects